Craneware Delivers Positive FY25 Results, Analysts Reaffirms ‘Buy’ Rating with 19% Upside

Craneware reported a 12% YoY increase in adjusted EBITDA to over $65 million in FY25, with revenue rising 9% to $205.7 million, surpassing market expectations.

Sonal Goyal | 18 July 2025

AstraZeneca Earns Buy Rating with 28% Upside Potential on Regulatory Wins and Encouraging Pipeline

Recent EU and U.S. approvals for Imfinzi and Datopotamab Deruxtecan bolster the company’s oncology portfolio.

Team Kalkine | 10 July 2025

BSF Enterprise (LSE:BSFA) Signs Exclusive Global IP Agreement for LiQD Cornea Technology

BSF Enterprise PLC (LSE:BSFA), a UK-based biotechnology company focused on tissue-engineered materials, announced on 10 July 2025 that its wholly owned subsidiary, Kerato Limited, has entered into an exclusive worldwide option agreement with Université de Montréal. The agreement grants Kerato the global rights to …

Team Kalkine | 10 July 2025

Aptamer Group Raises AUD 3.8 Million via Share Placing to Support Growth and Licensing Pipeline

Highlights

Team Kalkine | 04 July 2025

Avacta (LSE:AVCT) Reports Clinical Progress and Board Changes Ahead of AGM

Avacta Therapeutics plc (LSE:AVCT),a UK-based clinical-stage life sciences company, provided a business update ahead of its 2025 Annual General Meeting, outlining recent progress across its oncology pipeline and key corporate developments.

Team Kalkine | 02 July 2025

Spire Healthcare Earns Double BUY Ratings with Up to 31% Upside Potential

Highlights

Team Kalkine | 26 June 2025

Avacta Therapeutics Reports FY24 Results, Sharpens Focus on Oncology Drug Development

Highlights

Team Kalkine | 06 June 2025

Dr. Martens Charts Path to Profit Recovery in FY26 Following Strategic Reset

Highlights

Team Kalkine | 05 June 2025

hVIVO Faces Contract Cancellation and Trial Postponement Amid Sector Uncertainty

hVIVO plc (LSE:HVO)is a UK-based contract research organisation specialising in human challenge clinical trials. The company also offers laboratory and early-phase clinical trial services through its subsidiaries, including CRS and Venn.

Team Kalkine | 30 May 2025

ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

ANGLE plc (LSE:AGL),a UK-based liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has released its audited preliminary financial results for the year ended 31 December 2024. The company reported a reduction in operating loss alongside a revenue increase, following operational restructuring and …

Team Kalkine | 28 May 2025

Healthcare

Craneware Delivers Positive FY25 Results, Analysts Reaffirms ‘Buy’ Rating with 19% Upside

AstraZeneca Earns Buy Rating with 28% Upside Potential on Regulatory Wins and Encouraging Pipeline

BSF Enterprise (LSE:BSFA) Signs Exclusive Global IP Agreement for LiQD Cornea Technology

Aptamer Group Raises AUD 3.8 Million via Share Placing to Support Growth and Licensing Pipeline

Avacta (LSE:AVCT) Reports Clinical Progress and Board Changes Ahead of AGM

Spire Healthcare Earns Double BUY Ratings with Up to 31% Upside Potential

Avacta Therapeutics Reports FY24 Results, Sharpens Focus on Oncology Drug Development

Dr. Martens Charts Path to Profit Recovery in FY26 Following Strategic Reset

hVIVO Faces Contract Cancellation and Trial Postponement Amid Sector Uncertainty

ANGLE Reports FY2024 Results with Narrowed Loss and Continued Focus on Pharma Collaborations

Latest News

Is LSE:IOF One Of The Strongest Commodity-Linked Growth Stories On AIM?

Can Pantheon Resources Deliver on Its Alaska Oil Potential?

Is Altona Rare Earths a Hidden Rare Earth Opportunity?

Are UK Industrial Stocks Like Castings Undervalued?

How Does Market Volatility Affect CMCX Revenue?

Can Nanoco Survive as a Microcap Technology Stock?